| Database ID | Agent | Target | Cancer Type | Detail |
| DB00961 | Dabrafenib trametinib | NA | melanoma | view |
| DB00962 | Nivolumab and Ipilimumab | NA | melanoma | view |
| DB00963 | Bortezomib and Sorafenib | NA | melanoma | view |
| DB00964 | vemurafenib | BRaf protooncogene
serine/threonineprotein kinase | melanoma | view |
| DB00965 | Dabrafenib, trametinib | NA | melanoma | view |
| DB00966 | Bevacizumab, ipilimumab | NA | melanoma | view |
| DB00967 | sorafenib | Vascular endothelial growth factor receptor 1
BRaf protooncogene serine/threonineprotein kinase
Protooncogene tyrosineprotein kinase receptor ret | melanoma | view |
| DB00968 | vemurafenib | BRaf protooncogene
serine/threonineprotein kinase | melanoma | view |
| DB00969 | everolimus, cetuximab | NA | advanced solid tumors | view |
| DB00970 | sorafenib | Vascular endothelial growth factor receptor 1
BRaf protooncogene serine/threonineprotein kinase
Protooncogene tyrosineprotein kinase receptor ret | melanoma | view |
| DB00971 | foretinib | Vascular endothelial growth factor receptor 2
Hepatocyte growth factor receptor | renal cell carcinoma | view |
| DB00972 | vemurafenib | BRaf protooncogene
serine/threonineprotein kinase | melanoma | view |
| DB00973 | MK0457 | Aurora kinase A
Serine/threonine protein kinase 12
Protooncogene tyrosineprotein kinase LCK | advanced solid tumors | view |
| DB00974 | sorafenib | Vascular endothelial growth factor receptor 1
BRaf protooncogene serine/threonineprotein kinase
Protooncogene tyrosineprotein kinase receptor ret | advanced solid tumors | view |
| DB00975 | MEK162 | Dual specificity mitogenactivated protein kinase kinase | melanoma | view |